Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBITDA Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EBITDA Margin for 14 consecutive years, with 12.99% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 254.0% to 12.99% in Q4 2025 year-over-year; TTM through Dec 2025 was 5.98%, a 395.0% increase, with the full-year FY2025 number at 4.36%, down 192.0% from a year prior.
  • EBITDA Margin was 12.99% for Q4 2025 at Aytu Biopharma, down from 10.83% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 16.78% in Q4 2023 to a low of 220.76% in Q1 2022.
  • A 5-year average of 36.27% and a median of 12.99% in 2025 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -10019bps in 2021, then soared 18311bps in 2023.
  • Aytu Biopharma's EBITDA Margin stood at 48.84% in 2021, then surged by 47bps to 25.85% in 2022, then skyrocketed by 165bps to 16.78% in 2023, then plummeted by -162bps to 10.45% in 2024, then dropped by -24bps to 12.99% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EBITDA Margin are 12.99% (Q4 2025), 10.83% (Q3 2025), and 17.79% (Q2 2025).